India's DCGI withdrew AstraZeneca's Olaparib for specific cancer treatments due to safety concerns.

India's Drug Controller General (DCGI) has ordered the withdrawal of AstraZeneca's anti-cancer drug, Olaparib, for specific treatments due to safety concerns. The decision comes after clinical studies revealed the drug's potential negative impact on overall survival in cancer patients who have received three or more prior lines of chemotherapy. The drug remains available for other approved indications.

Articles

The Telegraph India

The Hindu Business Line

ProKerala

Siasat Daily

The Economic Times

Oneindia

LatestLY

The Telegraph India

-- show less --

Further Reading

Related Stories